GSK's asth­ma bi­o­log­ic Nu­cala is one step clos­er to ap­proval in key chron­ic rhi­nos­i­nusi­tis pop­u­la­tion

Months af­ter GSK’s Nu­cala cleared in a piv­otal rare blood dis­or­der study, the asth­ma bi­o­log­ic has scored in a late-stage tri­al in chron­ic rhi­nos­i­nusi­tis pa­tients with nasal polyps.

The British drug­mak­er on Fri­day dis­closed da­ta from the SYNAPSE study, which test­ed Nu­cala (al­so known as mepolizum­ab) against a place­bo on top of stan­dard-of-care in more than 400 pa­tients, all of whom had a his­to­ry of pre­vi­ous surgery (ap­prox­i­mate­ly one in three had ≥3 surg­eries) and re­quired surgery due to se­vere symp­toms and big­ger polyps.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER